
Improving Care Access and Utilization for Parkinson Disease: James Beck, PhD
The senior vice president and chief scientific officer of the Parkinson’s Foundation discussed a recently published Medicare claims analysis that highlighted significant issues with access to proper care for patients with Parkinson disease. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
"It’s these other clinicians, particularly neurologists, and provide them with the tools that they need as part of the process. [We need to] raise awareness about the [Parkinson’s] Foundation. We have a lot of tools that can answer basic questions that can reduce physician burden."
Inconsistent symptom presentation and disease progression, as well as lack of biomarker or objective clinical diagnostic test to diagnose disease, creates a challenge for diagnosing and treating Parkinson disease (PD), especially for physicians with less expertise in movement disorders. Recently published in Nature, a Medicare claims study by the
Led by
In 2019, findings showed that 20.3% of the population of Medicare beneficiaries living with PD used physical therapy, 9.5% used occupational therapy, and 7.5% used speech-language therapy. Additionally, despite more than half (52.9%) of Medicare beneficiaries having a diagnosis of depression and/or anxiety, only 1.8% of these individuals had at least 1 clinical psychology visit and 3.9% had at least 1 psychiatry visit.
After the study was published, Beck, senior vice president and chief scientific officer of the Parkinson’s Foundation, sat down to discuss the findings. He spoke on the main takeaways from the study, ways to bridge gaps in access to PD care, and overcoming challenges with the limited number of movement disorder specialists.
REFERENCE
1. Pearson C, Hartzman A, Munevar D, et al. Care access and utilization among medicare beneficiaries living with Parkinson’s disease. npj Parkinson’s Disease. Published online July 10, 2023. doi:10.1038/s41531-023-00523
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.






































